Neurol. praxi. 2023;24(2):111-115 | DOI: 10.36290/neu.2022.075
COVID-19 in patients with multiple sclerosis treated with ofatumumab
- Neurologické oddělení, Krajská nemocnice T. Bati, a. s., Zlín
When the global COVID-19 pandemic began in 2019, there were concerns about the course among patients with multiple sclerosis (MS). It seems that the course of this infection in MS patients is similar to the general population, given the same risk factors. Patients with comorbidities, patients on anti-CD20 therapy and after recent administration of corticosteroids progress to more clinically severe forms. Ofatumumab is a fully human anti-CD20 monoclonal antibody approved for treatment of adult patient with active relapsing-remitting MS (RR MS). The most recently published results from the open-label ALITHIOS study do not indicate that patient treated with ofatumumab are at increased risk of severe COVID-19. The issue of vaccination has been discussed for a long time in the context of potential risk and, on the other hand, because of the sufficient effectiveness of vaccination against SaRS-CoV-2 infection in patients treated with anti-CD20 therapy.
Keywords: multiple sclerosis, ofatumumab, COVID-19, vaccination.
Received: November 22, 2022; Revised: December 7, 2022; Accepted: December 10, 2022; Prepublished online: December 10, 2022; Published: April 21, 2023 Show citation
References
- Berlit P. Leitlinien für Diagnostik und Therapie in der Neurologie der Kommission Leitlinien der Deutschen Gesellschaft für Neurologie in Zusammenarbeit mit der Deutschen Gesellschaft für NeuroIntensiv‑und Notfallmedizin und der Deutschen Gesellschaft für HNO‑Heilkunde, Kopf‑und Hals‑Chirurgie publiziert bei. Available from: www.awmf.org.
- Cross AH, Delgado S, Habek M, et al. COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab. Neurol Ther. 2022;11(2):741-758.
Go to original source... 
Go to PubMed... - El‑Sayed A, Aleya L, Kamel M. Covid-19: a new emerging respiratory disease from the neurological perspective. Environmental Sci Pollution Research. 2021. https://doi. org/10.1007/s11356-021-12969-9. Go to original source... Go to PubMed...
- European Centre for Disease Prevention and Control - Immune responses and immunity to SARS‑CoV-2. Available from: https://www.ecdc.europa.eu/en/covid-19/latest‑evidence/immune‑responses.
- Hauser SL, Bar Or A, Cohen JA, et al. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383:546-557. Go to original source... Go to PubMed...
- Hauser SL, Cross H, Winthrop A, et al. Long‑term efficacy of ofatumumab in patients with relapsing multiple sclerosis. AAN. 2022: P5.005. Go to original source...
- Hauser SL, Cross H, Winthrop A, et al. Long‑term efficacy of ofatumumab in patients with relapsing multiple sclerosis. AAN. 2022: P5.005. Go to original source...
- Keyhanian K, Umeton RP, Mohit B, Davoudi V, Hajighasemi F, Ghasemi M. SARS‑CoV-2 and nervous system: from pathogenesis to clinical manifestation. J Neuroimmunol. 2021;350:577436. https://doi.org/10.1016/j.jneuroim. 2020; 577-436. Go to original source...
- Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology. 2020;77(9). https://doi.org/10.1001/jamaneurol.2020.2581. Go to original source... Go to PubMed...
- Maggi E, Canonica GW, Moretta L. Covid-19: Unanswered questions on immune response and pathogenesis. Journal of Allergy and Clinical Immunology. 2020;146(1):18-22. https://doi.org/10.1016/j.jaci.2020. 05. 001. Go to original source... Go to PubMed...
- Möhn N, Konen FF, Pul R, et al. Experience in multiple sclerosis patients with covid-19 and disease‑modifying therapies: a review of 873 published cases. J Clin Med. 2020;9:4067. doi:10.3390/jcm9124067. Go to original source... Go to PubMed...
- Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS‑CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurology. 2021. https://doi.org/10.1001/jamaneurol.2021.0688. Go to original source... Go to PubMed...
- Sormani MP, de Rossi N, Schiavetti I, et al. Disease‑Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology. 2021;89(4). https://doi.org/10.1002/ana.26028. Go to original source... Go to PubMed...
- Sospedra M. B cells in multiple sclerosis. Current Opinion in Neurology. 2018;31(3):256-262. Go to original source... Go to PubMed...
- Stastna D, Menkyova I, Drahota J, et al. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. Mult Scler Relat Disord. 2021; 54:103104. doi:10.1016/j.msard.2021.103104. Go to original source... Go to PubMed...
- SÚKL. Available from: https://www.ema.europa.eu/en/documents/product‑information/kesimpta‑epar‑product‑information_cs.pdf.
- Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology. 2006;177(1):362-371. Go to original source... Go to PubMed...
- Wang MY, Zhao R, Gao LJ F, et al. SARS‑CoV-2: structure, biology, and structure‑based therapeutics development. Front Cell Infect Microbiol. 2020;10:587269. doi: 10.3389/fcimb.2020.587269. Go to original source... Go to PubMed...
- Ziemssen T, Bopp T, Ettle B, et al. Kyrios clinical trial: Tracking tje immune response to SARS‑CoV-2 mRNA vaccines in an open‑label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab. AAN. 2022: P1.288. Go to original source... Go to PubMed...